Matthew L. Hemming, Ph.D. - Publications
Affiliations: | 2007 | Harvard University, Cambridge, MA, United States |
Area:
http://www.researchprofiles.collexis.com/jad/expert.asp?u_id=1Year | Citation | Score | |||
---|---|---|---|---|---|
2009 | Hemming ML, Elias JE, Gygi SP, Selkoe DJ. Identification of beta-secretase (BACE1) substrates using quantitative proteomics. Plos One. 4: e8477. PMID 20041192 DOI: 10.1371/Journal.Pone.0008477 | 0.566 | |||
2008 | Hemming ML, Elias JE, Gygi SP, Selkoe DJ. Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements. Plos Biology. 6: e257. PMID 18942891 DOI: 10.1371/Journal.Pbio.0060257 | 0.552 | |||
2007 | Hemming ML, Patterson M, Reske-Nielsen C, Lin L, Isacson O, Selkoe DJ. Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. Plos Medicine. 4: e262. PMID 17760499 DOI: 10.1371/Journal.Pmed.0040262 | 0.586 | |||
2007 | Hemming ML, Selkoe DJ, Farris W. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. Neurobiology of Disease. 26: 273-81. PMID 17321748 DOI: 10.1016/J.Nbd.2007.01.004 | 0.611 | |||
2005 | Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. The Journal of Biological Chemistry. 280: 37644-50. PMID 16154999 DOI: 10.1074/Jbc.M508460200 | 0.611 | |||
2005 | Farris W, Leissring MA, Hemming ML, Chang AY, Selkoe DJ. Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. Biochemistry. 44: 6513-25. PMID 15850385 DOI: 10.1021/Bi0476578 | 0.567 | |||
Show low-probability matches. |